Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1996 Feb;122(2):102–108. doi: 10.1007/BF01226267

Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations ofN 4-alkyl derivatives of 1-β-d-arabinofuranosylcytosine

R A Schwendener 1,✉, D H Horber 1, B Odermatt 2, H Schott 3
PMCID: PMC12200313  PMID: 8576276

Abstract

The oral cytostatic activity in L1210 mouse leukaemia of the two newN 4-alkyl derivatives of 1-β-d-arabinofuranosylcytosine (AraC),N 4-hexadecyl- andN 4-octadecyl-1-β-d-arabinofuranosylcytosine (NH- AraC, NO-AraC) was investigated. In contrast to AraC, both derivatives were highly cytostatic after oral application as liposome formulations. With treatment schedules of five consecutive dosages or with two applications on days 1 and 4 after intravenous tumour cell inoculation with a total dose of 470–1000 mg/kg NH- AraC or NO-AraC, 70%–100% of the treated animals were cured. The lethal dose in healthy ICR mice after a single intraperitoneal application, corresponding to the LD50, was 524 mg/kg for NO-AraC, whereas NH- AraC proved to be less toxic. The haematological toxicity. remained moderate for both drugs with a mild leucopenia and a drop in platelet counts, which recovered 4–6 days after treatment. The erythrocytes were not affected and haemolytic toxicities were absent. As non-haematological toxicities, at high drug concentrations, a pronounced atrophy of the rapidly dividing epithelia of the small intestines and of the white pulp of the spleen were observed. The blood levels of NH-AraC given orally reached values comparable to those after parenteral application of a four-times lower dose of NH-AraC, suggesting a moderate bioavailability. Thus, these two lipophilic derivatives of AraC are compounds with a potential for the oral treatment of malignant diseases.

Key words: Lipophilic AraC derivatives, Oral activity, Toxicity, Pharmacokinetics, Liposomes

Abbreviations

NH-AraC

N 4-hexadecyl-1-β-d-arabino-furanosylcytosine

NO-AraC

N 4-octadecyl-1-β-d-arabinofuranosylcytosine

AraC

1-β-d-arabinofuranosylcytosine

References

  1. Allen TM (1989) Stealth-liposomes: avoiding reticuloendothelial uptake. In: Lopez-Berenstein G, Fidler IJ (eds) Liposomes in the therapy of infectious diseases and cancer. Liss, New York, pp 405–415 [Google Scholar]
  2. Braess, J, Ramsauer B, Hiddemann W, Burk K, Schüssler M, Keye S, Schleyer E (1994) Pharmacokinetics of YNK01 (fosteabine)-the oral derivative of cytosinearabinoside. Ann Oncol S5:1738186162 [Google Scholar]
  3. Chabner BA (1990) Cytidine analogues. In: Chabner BA, Collins JM (eds) Cancer chemotherapy, principles and practice. Lippincott, Philadelphia, pp 154–179 [Google Scholar]
  4. Hellström-Lindberg E, Robert KH, Gahrton G, Lindberg G, Forsblom AM, Kock Y, Ost A (1994) Low-dose ara-C in myelodysplastic syndromes (MSD) and acute leukaemia following MSD: proposal for a predictive model. Leuk Lymphoma 12:343–351 [DOI] [PubMed] [Google Scholar]
  5. Heuvel MJ van den, Clark DG, Fielder RJ, Koundakarjian PP, Oliver GJ, Pelling D, Tomlison NJ, Walker AP (1990) The international validation of a fixed-dose procedure as an alternative to the classical LD50 test. Food Chem Toxicol 28:469–482 [DOI] [PubMed] [Google Scholar]
  6. Ho DHW, Frei E (1971) Clinical pharmacology of 1-β-D-arabino-furanosylcytosine. Clin Pharmacol Ther 12:944–954 [DOI] [PubMed] [Google Scholar]
  7. Ho DH, Carter CJ, Loo TL, Abbott RL, McBride CM (1975) Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs. Drug Metab Dispos 3:309–313 [PubMed] [Google Scholar]
  8. Hope MJ, Bally MB, Webb G, Cullis PR (1985) Production of large unilamellar vesicles by a rapid procedure, characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812:55–65 [DOI] [PubMed] [Google Scholar]
  9. Horber DH, Schott H, Schwendener RA (1995a) Pharmacokinetic properties and interactions with blood components ofN4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J Pharm Pharmacol 47:282–288 [DOI] [PubMed] [Google Scholar]
  10. Horber DH, Schott H, Schwendener RA (1995b) Cellular pharmacology of a liposomal preparation ofN4-hexadecyl-1-β-D-arabinofuranosylcytosine a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 71:957–962 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Horber DH, Ballmoos P von, Schott H, Schwendener RA (1995c) Cell cycle dependent cytotoxicity and induction of apoptosis byN4-hexadecyl-1-β-D-arabinofuranosyl-cytosine, a new lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer (in press) [DOI] [PMC free article] [PubMed]
  12. Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ (1992) Evolution of treatment for acute myelogenous leukaemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985–1991. Leukaemia 6[Suppl 2]: 78–80 [PubMed] [Google Scholar]
  13. Kodama K, Morozumi M, Saitoh K, Kuninaka A, Yoshino H, Saneyoshi M (1989) Antitumor activity and pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate: an orally active derivative of 1-β-D-arabinofuranosylcytosine. Jpn J Cancer Res 80:679–685 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ, Kyungmann K (1992) The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III study. Ann Haematol 65:162–168 [DOI] [PubMed] [Google Scholar]
  15. Neil GL, Moxley TE, Manak RC (1970) Enhancement by tetrahydrouridine of 1-β-D-arabinofuranosylcytosine (Cytarabine) oral acivity in L1210 leukemic mice. Cancer Res 30:2166–2172 [PubMed] [Google Scholar]
  16. Ohno R, Hirano M, Yamagata K, Ohara K, Shirakawa S, Hirota, Kobayashi M, Yoshikawa S, Mitomo Y, Ikeda Y, Tokai blood Cancer Study Group (1986) Treatment of leukaemia and myelodysplastic syndromes with orally administeredN4-palmitoyl-1-β-D-arabinofuranosylcytosine. Cancer Chemother Pharmacol 17:161–164 [DOI] [PubMed] [Google Scholar]
  17. Ohno R, Tatsumi N, Hirano M, Imai K, Mizoguchi H, Nakamura T, Kosaka M et al. (1991) Treatment of myelodysplastic syndromes with orally administred 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate. Oncology 48:451–455 [DOI] [PubMed] [Google Scholar]
  18. Rosowsky A, Kim SH, Ross J, Wick MM (1982) Lipophilic 5′-(alkyl phosphate) esters of 1-β-D-arabinofuranosylcytosine and itsN4-acyl and 2,2′-anhydro-3′-O-acylderivatinves as potential prodrugs. J Med Chem 25:171–178 [DOI] [PubMed] [Google Scholar]
  19. Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H, Schott H, Schwendener RA (1986) Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 37:149–154 [DOI] [PubMed] [Google Scholar]
  20. Schott H, Häussler MP, Schwendener RA (1994) Synthese von 4-Alkylcytosinnucleosiden und deren cytostatische Widkung im L1210 Läukemiemodell der Maus. Liebigs Ann Chem 465
  21. Schwendener RA, Schott H (1992) Treatment of L1210 murine leukemia with liposome-incorporatedN4-hexadecyl-1-β-D-arabinofuranosylcytosine. Int J Cancer 52:1–4 [DOI] [PubMed] [Google Scholar]
  22. Schwendener RA, Horber DH, Ottiger C, Schott H (1995) Preclinical properties ofN4-hexadecyl-andN4-octadecyl-1-β-D-arabinofuranosylcytosine in liposomal preparations. J Liposome Res 5:27–47 [Google Scholar]
  23. Thomson ABR, Schoeller C, Keelan M, Smith L, Clandinin MT (1993) Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol 71:531–555 [DOI] [PubMed] [Google Scholar]
  24. Tsuruo T, Tsukagoshi S, Sakurai Y (1980),N4-Palmitoyl-andN4-stearoyl-1-β-D-arabinofuranosylcytosine as new antitumor agent. In: Grassi JD (ed) Current chemotherapy and infectious disease. American Society of Microbiology, Washington, DC, pp 1591–1593 [Google Scholar]
  25. Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T (1994) Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administred long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 54:109–113 [PubMed] [Google Scholar]
  26. Wempen I, Miller N, Falco EA, Fox JJ (1968) Nucleosides. XLVII. Synthesis of someN4-substituted derivatives of 1-β-D-arabinofuranosyl cytosine and-5-fluorocytosine. J Med Chem 11:144–148 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES